http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021190583-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36c66685971b78daf233b5999ead4c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b5454abd09f216530c44daae0e81afa
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-22
filingDate 2021-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5b29740c48ee7526474923c33393833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df1c5cc2dfdf9e9d09a523950047c87c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91c82c7b3976831b4170dc1cf6cba3f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cf6993b93d3a3b684602be845046887
publicationDate 2021-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021190583-A1
titleOfInvention Anti-psma antibody-exatecan analogue conjugate and medical use thereof
abstract Provided are an anti-PSMA antibody-Exatecan analogue conjugate and medical use thereof. Specifically, provided is an anti-PSMA antibody-drug conjugate represented by general formula (Pc-L-Y-D), wherein Pc is an anti-PSMA antibody or an antigen-binding fragment thereof.
priorityDate 2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106999517-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5208020-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0737686-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007002222-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10195175-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013096771-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013106717-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104755494-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2907824-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03034903-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005238649-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005020645-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107735090-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020063676-A1

Total number of triples: 44.